Additional studies of biopsy needle diagnosed cases are needed to evaluate the clinical usefulness of stratifying prostate cancers by their PSA/Ki67 staining characteristics, and furthermore to define the best scoring method and relevant cut-off values. This evidence concerns the gene MKI67 and prostate cancer.